{"denoms":[{"counts":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"302"}],"units":"Participants"}],"groups":[{"description":"Participants received everolimus 10 mg once daily BSC throughout the study","id":"BG000","title":"Everolimus + BSC"},{"description":"Participants received matching placebo once daily plus BSC during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period","id":"BG001","title":"Placebo+BSC"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.70","value":"62.9"},{"groupId":"BG001","spread":"12.89","value":"59.4"},{"groupId":"BG002","spread":"12.18","value":"61.7"}]}]}],"description":"Age continuous at Baseline: Blinded Period","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"160"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"142"}],"title":"Male"}]}],"description":"Gender at Baseline: Blinded period","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"162"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"230"}],"title":"Caucasian"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"50"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"15"}],"title":"Black"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}],"title":"Other"}]}],"description":"Race at Baseline: Blinded-period","paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}